AcelRx: Stock Rockets In Anticipation For DSUVIA Launch
Seeking Alpha,
AcelRx is projected to launch its recently approved FDA DSUVIA in the second half of February.
AcelRx is projected to launch its recently approved FDA DSUVIA in the second half of February.
Nieuws Arjen Dijkgraaf | donderdag 14 februari 2019 Geneeskunde
David Goldman/AP Opioids disrupt the normal functioning of your brain, making it harder for people to quit and more vulnerable…
At a hearing on Capitol Hill earlier this year, U.S. Senator Lamar Alexander asked an important question: Why is most of the…